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Ligand-receptor binding kinetics is an emerging topic in the drug research community. Over the 
past years medicinal chemistry approaches from a kinetic perspective have been increasingly 
applied to G protein-coupled receptors including the adenosine receptors (AR), which are 
involved in a plethora of physiological and pathological conditions. The study of ligand-AR 
binding kinetics offers room for detailed structure-kinetics relationships next to more traditional 
structure-activity relationships. Their combination may facilitate the triage of candidate 
compounds in hit-to-lead campaigns. Furthermore, kinetic studies also help in understanding AR 
allosterism. Allosteric modulation may yield a change in the activity and conformation of a 
receptor resulting from the binding of a compound at a site distinct from where the endogenous 
agonist adenosine binds. Hence, in this review we summarize available data and evidence for the 
binding kinetics of orthosteric and allosteric AR ligands. We hope this review will raise 
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1.1. Adenosine receptors 
Adenosine receptors (ARs) belong to the superfamily of G protein-coupled receptors (GPCRs), 
the largest class of drug targets so far.1 ARs have four subtypes: A1AR, A2AAR, A2BAR and 
A3AR. Their activation by the endogenous agonist adenosine and subsequent signaling has been 
extensively studied.2,3 The A1 and A3 subtypes are mainly coupled to the enzyme adenylate 
cyclase in an inhibitory fashion via Gi/o proteins, whereas the A2A and A2B subtypes stimulate this 
enzyme via a Gαs protein.2,3 ARs are ubiquitously expressed throughout the human body and 
involved in a wide range of physiological and pathological conditions. For instance, the A1 and 
A2A ARs are present in the cardiovascular system and play critical roles in regulating myocardial 
oxygen consumption and coronary blood flow.4,5 These two receptors are also highly expressed in 
the brain, regulating the release of other neurotransmitters such as dopamine and glutamate.6 The 
A2B and A3 ARs are located mainly peripherally and are involved in many processes such as 
inflammation and immune responses.7,8  
Many selective orthosteric agonists and antagonists for ARs have been developed.9 Several 
clinical trials are currently in progress (see reviews10,11 and references therein for detailed 
information). One agonist targeting the A2A receptor, namely regadenoson, has been approved by 
the US Food and Drug Administration (FDA) for myocardial perfusion imaging in patients with 
suspected coronary artery disease.12 Istradefylline, a selective A2AAR antagonist, has received 
market approval in Japan for adjunctive treatment of Parkinson’s disease.13  
In addition to the extensive repertoire of orthosteric AR ligands—compounds that share the 
same binding site as adenosine —many allosteric modulators have been developed over the past 
decades.14 An allosteric modulator binds to a site on the target protein distinct from the 
orthosteric primary ligand binding site to which endogenous ligands such as adenosine and 
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synthetic derivatives bind.15 The binding of an allosteric modulator is supposed to cause a 
conformational change of the receptor, which, in turn, may enhance the action (affinity and/or 
efficacy) of a given orthosteric ligand (positive allosteric modulator, PAM) or inhibit it (negative 
allosteric modulator, NAM). In this light a ligand that occupies an allosteric site on a receptor but 
does not alter the action of the orthosteric ligand is termed a neutral allosteric ligand (NAL) or 
silent allosteric modulator (SAM).16-18 Furthermore, ‘bitopic’ or ‘dualsteric’ 
(orthosteric/allosteric) ligands bind to both orthosteric and allosteric sites, creating self-
allosterism.19-21 In principle, a strict allosteric modulator does not have any activity alone. It 
requires the presence of an orthosteric ligand (for instance, the endogenous hormone or 
neurotransmitter) to show its action. Therefore, an allosteric modulator of ARs could possibly 
tune the effect of endogenous adenosine in an event-responsive and temporally specific manner, 
which might have therapeutic advantages compared to an orthosteric AR ligand.22 
New insights into the molecular aspects of ligand binding stem from the X-ray 
crystallographic structure of GPCRs23, and the A2AAR is at the forefront in this regard.24 To date, 
several A2AAR structures in complex with an agonist25-27 or antagonist28-32 are available, which 
provide atomic details of ligand-receptor interactions and enable structure-based drug design and 
discovery for the AR and other GPCRs as well. The binding pocket of the A2AAR in complex 
with 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol 
(ZM241385) in an inactive state is depicted in Figure 1A, or with 6-(2,2-diphenylethylamino)-9-
((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-N-(2-(3-(1-(pyridin-2-
yl)piperidin-4-yl)ureido)ethyl)-9H-purine-2-carboxamide (UK432,097) in an active conformation 
(Figure 1B). In the inactive conformation (Figure 1A), the bicyclic triazolotriazine core of 
ZM241385 is anchored by an aromatic stacking interaction with Phe1685.29 (residue superscripts 
refer to the Ballesteros-Weinstein numbering33), an aliphatic hydrophobic interaction with 
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Ile2747.39 and a hydrogen bonding interaction with Asn2536.55. Adjacent to Phe1685.29 the polar 
residue Glu1695.30 interacts with the exocyclic amino group attached to the bicyclic core of 
ZM241385.28,32,34 Comparison of the active and inactive conformations of the A2AAR highlighted 
structural changes for receptor activation, particularly within the ligand binding region (Figure 
1B). These changes include a tightening of hydrophilic residues in TM3, TM5 and TM7 around 
the ribose group of UK432,097 (Thr883.36, Val843.32, Leu853.33, Ser2777.42, His2787.43).25 Unstable 
water molecules that appear in the inactive state of the A2AAR are removed from deep in the 
binding pocket.28,29,32 The 1.8-angstrom high-resolution crystal structure also identified the 
presence of a sodium ion, a general allosteric modulator for GPCRs, and several clusters of 
structural water molecules with potential roles in receptor stabilization and function.32 Crystal 
structures for A1, A2B and A3 ARs are not available yet. Although probing the binding sites of 
orthosteric and allosteric ligands for these subtypes largely relies on homology modeling and 
docking35,36 or on site-directed mutagenesis studies37-39, the predictability has been satisfactory, as 
evidenced by the identification, design and modification of both known and novel AR 
ligands.24,40-42  
 
1.2. Ligand-receptor binding kinetics as an emerging concept 
Ligand-receptor binding kinetics is an emerging pharmacological concept, which is receiving 
increasing attention in the drug research community. Several recent reviews have highlighted the 
importance of kinetic profiling in the pipeline of the drug design and discovery process. It allows 
resolving ligand-receptor interactions into both molecular recognition (kon) and complex stability 
(koff) and thus provides additional parameters for triage and advancement of drug candidates in 
the hit-to-lead campaign.43-45 For instance, several seminal studies in the field showed, in 
retrospect, that drugs with desirable receptor residence time (RT = 1 /koff)46 might provide the 
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following advantages: for therapies aiming for prolonged target occupancy, a long-RT compound 
might exert sustained pharmacological effects even if the compound has a rapid pharmacokinetic 
profile;47 on the other hand, when a drug’s target-related toxicity outweighs its therapeutic 
benefit, a rapidly dissociating compound that displays short-lived intervention may reduce the 
occurrence of on-target toxicity.48 Although conceptually tempting, ligand-receptor binding 
kinetics is still in its infancy and has been largely neglected in the traditional drug discovery 
process. The prevailing strategy in current practice is largely based on steady-state metrics, e.g. 
affinity or potency values, as predictors for in vivo efficacy. However, the current high attrition 
rate, often due to insufficient clinical efficacy,  suggests that the equilibrium-based strategy might 
be too simplistic.49 Introducing analysis of binding kinetics, and in particular residence time in 
the earlier phase of the drug design and discovery process might provide a better predictor for in 
vivo efficacy, and thereby contribute to the development of a new generation of improved 
medicinal products.50-53 
Kinetic characterization of AR ligands is emerging but has not been thoroughly reviewed 
before. Here, without claiming to be exhaustive we summarize orthosteric ligands on all ARs 
with known kinetic information. We also review and discuss the kinetics of orthosteric ligands in 
the presence of an allosteric modulator, given that the modulatory effect is best understood in 
terms of the kinetics of the ligand-receptor interaction.  
 
1.3. Current methods to measure binding kinetics on ARs 
Over the years several approaches to measure binding kinetics have been developed, and new 
techniques are emerging as well. These methods have been well documented in several recent 
reviews.45,54,55 Here we focus on the commonly used kinetic assays on the ARs (Figure 2).  
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1.3.1. Kinetic association assay 
As shown in Figure 2A, the association experiment is usually initiated by incubating the receptor-
bearing material with a ligand either radiolabeled or fluorescently labeled for a different period. 
kobs, the observed rate constant to approach equilibrium, can be obtained by Equation (1) and then 
fitted into Equation (2) to obtain the ligand’s association rate (kon). 
Y = Ymax ∙ (1 - e- kobs ∙ t) (1) 
kon = (kobs - koff) / [labeled ligand] (2) 
Where t is a given time, Y is the amount of specific labeled ligand binding, Ymax the specific 
labeled ligand binding at equilibrium, koff the dissociation rate constant being determined in 
independent dissociation experiments as follows.  
1.3.2. Kinetic dissociation assay 
Firstly, the receptor-bearing material is pre-incubated with the labeled ligand to reach 
equilibrium. Secondly, an excess amount of assay buffer (i.e., infinite dilution) or a receptor-
saturating concentration of unlabeled ligand is added to prevent ligand (re)association (Figure 
2B). In this way labeled ligand dissociation is initiated, which usually follows a monophasic or 
biphasic exponential decay depending on different mechanisms. 
1.3.3. Competition association assay 
An alternative that avoids labeling every ligand of interest is the competition association assay 
(Figure 2C), in which a labeled ligand is co-incubated with the receptor-bearing material in the 
absence (i) or presence of an unlabeled ligand of interest (ii and iii). With this method the 
association and dissociation rate constants for unlabeled ligands are calculated by fitting the data 































































Where X is the time, Y is the specific binding of the labeled ligand, k1 the kon of the labeled 
ligand predetermined in association experiments, k2 the koff predetermined in dissociation 
experiments, L the concentration of the labeled ligand used, Bmax the total binding and I the 
concentration of unlabeled ligand. Combining these parameters into Equation (3) allows the 
following parameters to be calculated: k3, the kon of the unlabeled ligand and k4, the koff of the 
unlabeled ligand.  
Different kinetic profiles of an unlabeled ligand are also reflected in the kinetic association 
curves (Figure 2C). According to the theory of Motulsky and Mahan56, if the competitor 
dissociates faster from its target than the labeled ligand, the specific binding of the radioligand 
will slowly and monotonically approach its equilibrium in time (ii). However, when the 
competitor dissociates more slowly, the association curve of the labeled ligand will consist of two 
phases starting with a typical ‘overshoot’ and then a decline until a new equilibrium is reached 
(iii). This assay also allows further adaptation into a high-throughput format, which will be 
discussed in Section 2. 
1.3.4. Kinetic assay in the presence of an allosteric modulator 
The influence of an allosteric modulator on the binding kinetics of a given orthosteric ligand (the 
probe) is usually quantified in a dissociation experiment by determining the change in the probe’s 
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dissociation rate constant (Figure 2D). In brief, the assay contains the following phases: (1) 
formation of the probe-receptor binary complex by preincubating the receptor-bearing material 
with a probe; (2) addition of an allosteric modulator either before or together with the initiation of 
the probe’s dissociation—methods vary in different labs—to stabilize the allosteric ternary 
complex; (3) dissociation of the probe by adding a displacer in an excess amount or by an infinite 
dilution step. After a period of incubation, the allosteric activity is scored based on a comparison 
of the residual binding of the probe in the presence (i) or absence (ii) of the allosteric modulator. 
A PAM will retard the probe’s dissociation from the receptor (as in Figure 2D), whereas a NAM 
will fasten the dissociation process.  
The on- and off-rate of a given orthosteric ligand in the presence of an allosteric ligand can 
also be quantified by the competition association assay, which was further adapted in our lab for 
the evaluation of allosteric activity using an unlabeled orthosteric ligand.57 The result obtained is 
very informative, which provides (1) a measure of the kinetic characteristics of a probe, including 
its association and dissociation rate constants and kinetic KD (koff/kon), and (2) an examination of 
a specific feature of GPCR allosteric modulation, the so-called “probe-dependency”16,58. 
1.3.5. Emerging approaches 
Alternative to the abovementioned filtration assays, the scintillation proximity assay (SPA) 
enable one to monitor dynamic ligand-AR interactions in a “mix and measure” format without a 
filtration step to separate bound from free ligand as is the case in a traditional receptor-binding 
assay. An application of the SPA assay is recently reported on the A1AR, demonstrating its 
practical convenience in kinetic measurements.59  
Kinetics of ligand-receptor interaction can be obtained by monitoring fluorescent ligand 
binding in combination with fluorescence correlation spectroscopy (FCS). This technique 
measures fluctuations in the fluorescence intensity of fluorescently labeled particles diffusing 
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through a small illuminated detection volume. This allows free ligands to be distinguished from 
slowly diffusing receptor-bound ligands without their physical separation.60 One major advantage 
of this method is that the actual ligand amounts can be measured. It can be used at the single cell 
level and even at the level of single molecules.54 Several cases were reported by Hill and 
coworkers, who characterized kinetic ligand binding to different ARs.61-64 
Furthermore, advances in label-free technology enable kinetic determinations of AR ligands 
as well, as represented by the surface plasmon resonance (SPR) technology65,66 or the more 
recently application of mass spectrometry67. 
 
2. ORTHOSTERIC LIGANDS’ BINDING KINETICS 
As mentioned above, the most straightforward and common way of measuring ligand-receptor 
binding kinetics is using a kinetic radioligand binding assay.45,54 Radiolabeled agonists or 
antagonists selective for each AR subtype are available. They are tool/reference compounds that 
can be applied to investigate the kinetics of known or novel unlabeled AR ligands using the 
mathematical model developed by Motulsky and Mahan.56 In the following section we will 
discuss the kinetic profile of orthosteric ligands for each AR subtype. 
 
2.1. A1AR 
Chemical structures of representative A1AR ligands are in Figure 3 and their binding kinetics is 




Table 1. Binding kinetics of A1AR ligands.  









CPA Rat brain tissue 23 5.5 × 107 0.023 0.42 68 
(S)-ENBA Rat brain membranes 25 1.2 × 108 0.056 (fast phase);  
0.0032 (slow phase) 
n.a. 69 
(R)-PIA Rat brain membranes 37 6.6×106  0.078 12 70 
(R)-IHPIA Rat brain membranes 30 3.1 × 107 1.3 (fast phase);  
0.0093 (slow phase) 
n.a. 71 
LUF5834 CHOhA1AR membranes 25 2.0 × 108 0.92 4.6 57 
Capadenoson CHOhA1AR membranes 25 2.4 × 107 0.036 1.5 72 
LUF6976 CHOhA1AR membranes 25 3.9 × 108 0.87 2.2 73 
LUF7050 CHOhA1AR membranes 25 4.3 × 105 0.016 37 73 
LUF6941 CHOhA1AR membranes 25 2.6 × 106 0.0076 2.9 72 
ABA-X-
BY630 
CHOhA1AR whole cells 37 2.6 × 107 2.0 77 74 
XAC Rat adipocyte membranes 25 3.0 × 107 0.12 4 75 
DPCPX Rat brain membranes 25 9.0 × 107 0.045 0.50 76 
DPCPX CHOhA1AR membranes 25 1.4 × 108 0.21 1.5 77 
I-BW-A844U Bovine brain membranes 19-
22 
6.7 × 108 0.093 0.14 78 
LUF5962 CHOhA1AR membranes 25 6 × 107 0.021 0.35 77 
LUF6057 CHOhA1AR membranes 25 4.8 × 108 3.0 6.3 77 
Kinetic KD = koff/kon. n.a., not applicable, KD values cannot be calculated due to the biphasic 
nature of the dissociation processes. 
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2.1.1. A1AR receptor agonists 
In general, most A1AR agonists are derivatives of the endogenous ligand adenosine (1), 
containing a ribose group attached to the N9 position of the adenine moiety. Substitution at the N6 
position with a wide range of alkyl, cycloalkyl or arylalkyl groups generally causes A1AR 
selectivity.9 Among these synthetic efforts, N6-cycloalkyl substitution yielded N6-
cyclopentyladenosine (2, CPA), which has become a reference compound to examine the 
pharmacology of the A1AR. Kinetic characterization of tritium-labeled CPA binding to the A1AR 
in rat brain tissue revealed its association rate of 5.5 × 107 M-1∙min-1 and dissociation rate of 
0.023 min-1, equaling a “kinetic KD” (koff/kon) of 0.42 nM.68 Its 2-chloro substituted analogue, 2-
chloro-N6-cyclopentyladenosine (3, CCPA), has a high selectivity for the A1AR too, combined 
with slow kinetics with equilibrium reached after three hours for both its association to and 
dissociation from the receptor.79,80 Replacing the cyclopentyl group in CPA with cyclohexyl 
resulted in N6-cyclohexyladenosine (4, CHA), which was reported to have a slow dissociation 
half-life (t1/2 = 60 min) from the A1AR in both guinea pig and bovine brain.81  
Substitution at the N6 position with bicycloalkyl groups can further improve the ligand’s 
selectivity compared to that with the monocycloalkyl moiety. One example is the development of 
1R,2S,4S-N6-2-endo-norbornyladenosine, [5, (S)-ENBA].69 It displayed a higher selectivity ratio 
(A2A/A1 Ki ratio = 4700) in rat brain membranes than CPA (A2A/A1 Ki ratio = 780). Kinetic 
characterization of the tritiated form of (S)-ENBA revealed that the compound had a fast 
association to the A1AR  (kon 1.2 × 108 M-1∙min-1). Its dissociation from the receptor was best 
fitted to a biphasic model (koff_1 = 0.056 min-1 for the fast dissociation phase and koff_2 = 0.0032 
min-1 for the slow dissociation phase), probably representing the kinetics at both low- and high-
affinity binding states.  
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Other lines of research, such as arylalkyl substitution at the N6 position of adenosine 
analogues, also led to the discovery of selective A1AR agonists (6-8), for instance, N6-[(R)-
phenylisopropyl]adenosine [6, (R)-PIA] and derivatives (7, 8). The binding kinetics of (R)-PIA 
was determined in rat brain membranes at 37 °C (kon = 6.58 × 106 M-1∙min-1,  koff = 0.078 min-1, 
kinetic KD = 12 nM).70 After this, Schwabe and colleagues reported a radioiodinated para-
hydroxy substituted analogue, namely [125I]-N6-(3-iodo-4-hydroxyphenylisopropyl)adenosine 
([125I]-IHPIA), and used it in its racemic form to characterize the A1AR in rat cerebral cortex 
membranes.82 In a follow-up study, Munshi et al. specifically synthesized and examined the 
respective kinetics of the iodinated stereoisomers of N6-(4-hydroxylphenyl)isopropyladenosine 
(HPIA), i.e., N6-[(R)-(3-iodo-4-hydroxyphenyl)isopropyl]adenosine [7, (R)-IHPIA] and N6-[(S)-
(3-iodo-4-hydroxyphenyl)isopropyl]adenosine [8, (S)-IHPIA] in rat brain membranes.71 In 
contrast to the fast binding of the (S)-isomer (less than 10 min for complete ligand association), 
the (R)-isomer interacted slowly with the receptor and required almost 2 h to reach equilibrium, 
when a concentration close to the Kd was used. The association rate was estimated with a kon 
value of 3.1 × 107 M-1∙min-1. The dissociation of specifically bound [125I]-(R)-IHPIA was 
biphasic, displaying an initial fast phase (1.3 min-1) followed by a slower phase (0.0093 min-1) 
comparable to that of (S)-ENBA mentioned above.  
5'-N-ethylcarboxamidoadenosine (9, NECA) is another radiolabeled agonist with well-
characterized binding kinetics. It displayed very fast kinetics on pig aorta smooth muscle 
membranes at 0 °C.83 Within 2 min more than half of the maximal binding of [3H]-NECA was 
attained. The dissociation of this radioligand was very rapid as well. Almost 80% of the 
specifically bound [3H]-NECA was displaced by 100 μM NECA within 1 min.  
Next to the classical derivatives of purine nucleosides as A1AR agonists, non-adenosine 





hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitril (13, capadenoson)86,87. Both compounds had 
(relatively) fast binding kinetics at a CHO cell line expressing the recombinant human A1AR 
(CHOhA1AR). In a follow-up study, the synthesis and evaluation of 4-amino-aryl-5cyano-2-
thiopyrimidines was reported by our group.73 These compounds displayed divergent kinetic 
profiles with ligand-receptor RTs ranging from 1 min (4-amino-6-(benzo[d][1,3]dioxol-5-yl)-2-
((2-morpholinothiazol-4-yl)methylthio)pyrimidine-5-carbonitrile, 11, LUF6976) to 1 h (4-amino-
6-(benzo[d][1,3]dioxol-5-yl)-2-((2-(4-iodophenyl)thiazol-4-yl)methylthio)pyrimidine-5-
carbonitrile, 12, LUF7050), and extensive structure-affinity (SAR) and structure-kinetics 
relationships (SKR) were established. A similar analysis of SAR and SKR for novel A1AR 
agonists was performed in another study, in which Louvel et al. reported the synthesis and 
biological evaluation of new derivatives of capadenoson.72 This allowed the discovery of 2-
amino-6-{[2-(4-chlorophenyl)thiazol-4-yl]methylthio}-4-(4-methoxyphenyl)pyridine-3,5-
dicarbonitrile (14, LUF6941) with an increased RT of 132 min, which is nearly 26-fold longer 
than that of 2-amino-4-(4-methoxyphenyl)-6-(thiazol-4-ylmethylthio)pyridine-3,5-dicarbonitrile 
(15, LUF7064)—an analogue without a phenyl group attached to the thiazole. These studies 
demonstrated that minor chemical modifications can have a dramatic effect on ligand-receptor 
residence time, while the affinity remains more or less the same (LUF6941, Ki = 5.0 nM; 
LUF7064, Ki = 1.3 nM). Such a drug development strategy of SAR in combination with SKR 
could be very useful in future kinetics-directed medicinal chemistry efforts.88,89 
In addition to the application of radiolabeled A1AR agonists for kinetic investigations new 
fluorescent agonists are available.60,62,90 In combination with scanning confocal microscopy and 
fluorescence correlation spectroscopy, these tool compounds allow noninvasive imaging and 
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quantification of the kinetics of ligand-receptor interactions in living single cells.91 One 
exemplary case is the fluorescent adenosine derivative ABA-X-BY630 (16), an N6-
aminobutyladenosine congener conjugated with the commercially available amine-reactive 
fluorophore BODIPY630/650-X.74 The fluorescent ligand had a relatively slow on-rate (2.6 × 107 
M-1∙min-1) and a fast off-rate (2.0 min-1) at CHOhA1AR cells. It can be argued that the attached 
large fluorophore and the long aliphatic linker to N6-aminobutyladenosine may strongly influence 
the overall kinetics of the fluorescent agonist.92 Considering this, it might be interesting to 
compare the kinetics of the parental agonist (N6-aminobutyladenoine) in another assay format 
under the same conditions (e.g. cell line, temperature, etc.) for better understanding of the 
fluorescent ligand’s binding kinetics.  
2.1.2. A1AR receptor antagonists 
Xanthine and xanthine derivatives, including the natural products caffeine (17) and theophylline, 
are prototypical antagonists at all AR subtypes.93 Chemical modifications of the xanthine core 
structure at the 8-position with aryl or cycloalkyl groups have led to antagonists with high affinity 
and selectivity for the A1AR.9 One of the first cases available with kinetic profiling dates back to 
1980, when Goodman et al. reported the dissociation rate of the tritiated 1,3-
diethylphenylxanthine (18, DPX).81 In bovine brain the antagonist exhibits high-affinity binding 
(Ki = 5 nM) and rapid dissociation kinetics (t1/2 = 1 min) measured at 0 °C. Following this study, 
Jacobson et al. prepared an amine-functionalized analogue of 1,3-DPX in tritiated form coined 
xanthine amine congener (19, XAC) for use as another antagonist radioligand.94 The kinetics for 
[3H]-XAC were later measured on rat adipocyte membranes and specifically examined for the 
effect of guanine nucleotides on ligand binding to the A1AR. It was shown that Gpp(NH)p 
(Guanosine 5’-[β,γ-imido]triphosphate), a nonhydrolyzable form of GTP, enhanced the 
association rate (kon = 3 × 107 M-1∙min-1) of the radioligand to the receptor by 4-fold (kon = 1.3 × 
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108 M-1∙min-1) but had no effect on the dissociation rate (koff = 0.12 min-1) of the radioligand-
receptor complex.75 A similar study was performed by Prater et al., in which the authors 
evaluated the effects of GTPγS [guanosine 5'-(3-O-thio)triphosphate], another nonhydrolyzable 
form of GTP, on the binding of radioiodinated 3-(4-amino-3-I-phenethyl)-1-propyl-8-
cyclopentylxanthine (20, I-BW-A844U)95 to the A1AR in bovine brain membranes.78 Contrary to 
the result for [3H]-XAC, the kinetics of 125I-BW-A844U were not significantly changed in the 
absence (kon = 6.0 × 108 M-1∙min-1, koff = 0.098 min-1) or presence (kon = 6.7 × 108 M-1∙min-1, koff 
= 0.093 min-1) of GTPγS, although the Bmax value was increased by 28%. Combining with other 
lines of evidence, Prater et al. confirmed that the effects of GTPγS could be attributed to the 
decreased affinity of receptors for a pool of endogenous adenosine that cannot be readily 
removed from membranes. Such a finding is important, especially for accurate kinetic 
measurements on tissue preparations.  
Further structural modifications on the xanthine core by means of combining 1,3-dipropyl- 
and 8-cyclopentyl substitutions led to additive effects for 8-cyclopentyl-1,3-dipropylxanthine (21, 
DPCPX) in terms of A1AR affinity and selectivity over other ARs.76 Additionally, the nonspecific 
binding of radiolabeled DPCPX was very low. Its properties are superior to those of other 
radioligands. Therefore, [3H]-DPCPX has been benchmarked for subsequent pharmacological 
and kinetic characterizations on the A1AR. Using rat brain membranes, Lohse et al. determined 
[3H]-DPCPX’s association and dissociation rate constants (kon = 9 × 107 M-1∙min-1, koff = 0.045 
min-1) for the first time, yielding a ‘kinetic KD’ of 0.5 nM. Notably, DPCPX displayed different 
binding kinetics at the recombinant CHOhA1AR membranes (kon = 1.4 × 108 M-1∙min-1, koff = 
0.21 min-1) at the same assay temperature57,77, suggesting species differences.88  
To allow kinetic characterizations in a high-throughput format, our group developed a so-
called dual-point competition association assay based on the mathematical model developed by 
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Motulsky and Mahan.56 The method measures radioligand binding at two different time points (t1 
and t2) and their ratio (binding at t2/binding at t1) in the presence of an unlabeled competitor 
coined the kinetic rate index (KRI).77 This approach enables direct comparison of ligand-receptor 
RTs, i.e. a KRI above 1.0 indicates a relatively slow dissociation from the target; a KRI below 1.0 
or equal to 1.0 predicts relatively fast or similar dissociation kinetics as the radioligand. With this 
method we were able to screen a large number of in-house A1AR antagonists and then rank their 
KRI values. We discovered the non-xanthine antagonists 8-cyclopentyl-2,6-diphenyl-7H-purine 
(22, LUF5962) and N-(6-(benzo[d][1,3]dioxol-5-yl)-5-cyano-2-phenylpyrimidin-4-yl)butyramide 
(23, LUF6057) have the highest and lowest KRI values, respectively. Consistently, these two 
compounds showed the slowest and fastest dissociation rates of 0.021 min-1 and 0.33 min-1, 
respectively, in a follow-up competition association assay. 
 
2.2. A2AAR  
Figure 4 has the chemical structures of representative A2AAR ligands. Their binding kinetics are 
summarized in Table 2. 
2.2.1. A2AAR receptor agonists 
One of the first kinetic investigations at the A2AAR was performed with the radiolabeled 2-[p-(2-
carboxyethyl)-phenethylaminol]-5'-N-ethylcarboxmido adenosine, (24, CGS21680). The ligand 
binds to the A2AAR in rat striatal membranes with an on-rate of 2.1 × 107 M-1∙min-1 and an off-
rate of 0.033 min-1, equaling to a RT of 31 min.96 Notably, two adenosine receptors (A1AR and 
A2AAR) are expressed in brain tissue at high levels.97,98 CGS21680 displayed a high affinity to 
the A2AAR (15 nM) while a 140-fold lower affinity was reported at the rat brain AlAR.99 This 
provides the advantage of directly labeling the A2AAR receptor for binding and kinetic 
determinations, without the need to block the A1AR. In contrast, when using nonselective 
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radioligands such as [3H]-NECA100 or [3H]-XAC101 in brain tissue/membrane preparations, the 
influence from the A1AR needs to be blocked. 
 
Table 2. Binding kinetics of A2AAR ligands.  






Kinetic KD  
(nM) 
Ref. 
CGS21680 Rat striatal membranes 23 2.1 × 107 0.033 1.6 96 
NECA HEK293hA2AAR membranes 4 1.9 × 106 0.053 28 102 
UK432,097 HEK293hA2AAR membranes 5 5.0 × 105 0.004 8.0 103 
LUF5835 HEK293hA2AAR membranes 5 1.6 × 107 0.29 18 103 
PD115,199 Rat striatal membranes 25 1.1 × 109 1.24 1.1 104 
XAC Rabbit striatal membranes 24 1.3 × 108 0.36 2.8 101 
SCH58261 CHOhA2AAR membranes 25 6.4 × 108 1.5 2.3 105 
ZM241385 HEK293hA2AAR membranes 4 1.3 × 108 0.014 0.11 106 
LUF6805 HEK293hA2AAR membranes 4 2.0 × 108 0.35 1.8 106 
LUF6632 HEK293hA2AAR membranes 4 3.4 × 107 0.0031 0.091 106 
34 Purified A2A-StaR 25 2.4 × 108 0.061 0.25 107 
Kinetic KD = koff/kon. 
 
The availability of a cell line stably expressing recombinant hA2AARs further provides 
convenience for kinetic investigations at one receptor subtype. This allows one to even use 
nonselective ligands for kinetic measurements. For instance, in our lab we determined the binding 
kinetics of [3H]-NECA on HEK293hA2AAR cell membranes by plotting its kobs values as a 
function of the concentrations.102 As a result, a significant linear correlation was observed, 
suggesting that the association of [3H]-NECA to the A2AAR follows a simple one-step process. 
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The kon and koff values derived from this method were 1.9 × 106 nM-1∙min-1 and 0.053 min-1, 
respectively, equaling to a kinetic KD of 27.9 nM. 
In another study from our lab, we used the Motulsky and Mahan competition association 
assay56 to analyze the binding kinetics for ten A2AAR full and partial agonists, including both 
adenosine-like and non-adenosine derivatives.103 A strong correlation was observed between the 
compounds’ receptor RTs and their intrinsic efficacies gathered from a cAMP assay and a cell-
based label-free impedance assay. On the contrary, the affinity of the A2AAR agonists was not 
correlated with efficacy. Of all ten agonists tested, UK432,097 (25) displayed the longest RT at 
the receptor. The structural basis for its long receptor occupancy was elucidated by Stevens and 
colleagues from the Scripps institute, when they determined the crystal structure of the A2AAR.25 
It was observed that the co-crystalized UK432,097 was accommodated in an extensive interaction 
network, including 11 hydrogen bonds, one strong aromatic stacking and a number of van der 
Waals interactions in the A2AAR/UK432,097 complex. In comparison, the non-adenosine agonist, 
2-amino-4-(3-hydroxyphenyl)-6-(1H-imidazol-2-ylmethylsulfanyl)pyridine-3,5-dicarbonitrile, 
(26, LUF5835), displayed the shortest receptor RT of 3.4 min. Such differences in kinetics 
highlight the structural importance of the ribose group, as demonstrated in several other 
adenosine-like agonist-bound crystal structures as well, in which the sugar moiety inserts deeply 
into the binding cavity and is stabilized by key residues such as S2777.42 and H2787.43.25,27,108  
The elucidation of the agonist-bound A2AAR structure also enabled molecular dynamics 
simulations of ligand-receptor interactions. Recently, Lee and Lyman reported microsecond-time 
scale simulations of the A2AAR bound to either adenosine or UK432,097.109 The binding of 
adenosine to the A2AAR was highly dynamic, in stark contrast to the case with UK432,097, 
which was stabilized in a much tighter neighborhood in the binding cavity. The two aromatic 
rings of UK432,097 blocked the entrance to the binding pocket, gating the access of water to the 
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interior of the protein, consistent with its long receptor RT. On the contrary, the binding pocket 
appears much more hydrated in the case of adenosine and thus the ligand has to constantly 
compete with water molecules to form transient hydrogen bonds. Furthermore, the authors also 
suggested the possibility of an additional binding site located closer to the extracellular entrance 
to the binding pocket. It is likely that such a binding site is vital along the trajectories of ligand 
association to and egress from the receptor, resembling the so-called “extracellular vestibule” on 
other GPCRs.110,111  
Based on the results mentioned above, several features that affect the kinetics of agonists at 
the A2AAR can be hypothesized. Firstly, upon binding agonists that contain a polar ribose group – 
which is true for the majority of adenosine receptor agonists - can form a number of hydrogen 
bonds with the receptor. This anchoring accommodates the ligand in the binding pocket, 
otherwise occupied by three water molecules. Secondly, the ligand’s dissociation process is 
influenced by the hydration state of the binding pocket after binding of the agonist. In a highly 
hydrated binding cavity, the bound ligand competes with water molecules to form polar 
interactions with the receptor. This possibly reduces the ligand’s residence time in the receptor, 
while ligands can stay longer in a less hydrated binding site. Thirdly, ligands that form transient 
interactions with the receptor along their dissociation trajectories might display longer residence 
times on the target, while not so for those with fewer interactions. 
2.2.2. A2AAR receptor antagonists 
Binding kinetics studies for A2AAR antagonists are emerging. This started from the application of 
tritium-labeled non-selective adenosine receptor antagonists, such as N-[2-
(dimethylamino)ethyl]-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-
yl)benzenesulfonamide (27, PD115,199)104 and XAC (19)101. The kinetics of both compounds 
were measured in the presence of an A1AR-selective antagonist to eliminate the binding to the 
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A1AR in rat/rabbit brain striatal membranes. Such an approach allowed a reliable determination 
of the A2AAR-related kinetics. XAC displayed rapid binding kinetics (kon = 1.3 × 108 M-1∙min-1, 
koff = 0.36 min-1) at 24 °C. The association and dissociation of PD115,199 was fast as well at a 
similar temperature (25 °C) with an on-rate of 1. 1 × 109 M-1∙min-1 and an off-rate of 0.36 min-
1.101,104 
In 1994, Nonaka et al. examined the potential of the radiolabeled 8-(3,4-
dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (28, KF17837S) as the first selective antagonist 
radioligand for the A2AAR.112 This compound was characterized with kinetics similar to that of 
[3H]-XAC, yet slower than [3H]-PD115,119. Another xanthine derivative with high A2AAR 
affinity and selectivity is 3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-
propargylxanthine (29, MSX-2), developed by Müller and colleagues.113 This xanthine derivative 
also displayed binding kinetics to the A2AAR in a similar range as the other aforementioned 
analogues. 
Non-xanthine antagonists have also been developed. Two examples are 7-(2-phenylethyl)-
5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (30, SCH58261) and 
ZM241385 (31). Both SCH58261 and ZM241385 have been prepared in a tritiated form114,115, the 
latter of which has also been available in a radioiodinated form116, enabling direct measurement 
of their on- and off-rates in kinetic radioligand binding assays. [3H]-SCH58261 showed fast 
association and dissociation at both rat striatal membranes114 and membranes from CHO cells 
stably transfected with the human A2AAR105 at 25 °C (rat: kon = 1.15 × 109 M-1∙min-1, koff = 1.12 
min-1; human: kon = 6.4 × 108 M-1∙min-1, koff = 1.5 min-1). Kinetics for [3H]-ZM241385 have been 
extensively studied in several studies, including characterizations at different temperatures103,115 
or at A2AAR membranes from different species117. Such abundant information, together with its 
ideal binding properties (i.e., low non-specific binding and high receptor affinity), benchmarked 
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ZM241385 as a proper reference compound for follow-up studies.103,106 One example is a 
combined SKR and SAR study from our group.106 An ensemble of 24 A2AAR antagonists, all 
ZM241385 derivatives with variations at the C2-position, displayed only minor differences in 
affinity, while they varied substantially in their dissociation rates from the receptor. Among these 
derivatives, N5-(2-(4-(3,4-difluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-
a][1,3,5]triazine-5,7-diamine (32, LUF6632), a high-affinity A2AAR antagonist previously 
synthesized and reported by Vu et al.118, showed the slowest dissociation rate (koff = 0.0031 min-
1), which was approximately five-fold slower than that of ZM241385. In comparison, 2-(furan-2-
yl)-N5-(2-(4-phenylpiperidin-1-yl)ethyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (33, 
LUF 6805) displayed the fastest dissociation rate of 0.35 min-1, equaling to a RT of 3 min. 
LUF6805 and LUF6632 was also compared in a cAMP assay using different formats (co-
application vs. pre-incubation). It appeared that LUF6632, rather than LUF6805,  was a 
competitive, insurmountable antagonist at the hA2AAR—a phenomenon caused by so-called 
hemi-equilibrium due to its long A2AAR residence time profile.119 
Next to the application of radioligand binding assays, several studies used surface 
plasmon resonance (SPR) measurement for binding and kinetic investigations. One of the 
examples is the discovery of 1,2,4-triazine derivatives as A2AAR antagonists, in which 4-(3-
amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol (34) displayed the slowest dissociation rate 
(0.061 min-1) while its analogue 5,6-diphenyl-1,2,4- triazin-3-amine (35) showed a dissociation 
rate more than 1000-fold faster.107 The crystal structure of the A2AAR in complex with 34 was 
elucidated, illustrating that the compound bound deeply inside the orthosteric binding cavity 
having significant interactions with Ile662.64, Leu853.33, Asn1815.42 and Asn2536.55. An analysis of 
the binding site in the apo A2AAR structure (with the co-crystalized ligand removed) 
demonstrated that the compound occupied exactly the same region where a cluster of “unhappy” 
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water molecules (> 2.2 kcal/mol vs bulk solvent) existed.120 Displacing these water molecules is 
entropically favorable, which perhaps accounts for the slow dissociation profile of 34.121 
It is important to mention that the required immobilization of the (purified) protein on the 
SPR chip can potentially block the accessibility of the intra- or extracellular side of the receptor, 
and may consequently affect ligand-receptor binding kinetics. The influence of lipid composition 
upon assay performance was recently investigated in a comparative study of the adenosine A2A 
receptor employing four different reconstitution approaches.66 When the receptor was 
reconstituted in lipid nanodiscs, protein stability was enhanced and the kinetic data obtained were 
more similar to native receptors compared with those solubilized in detergents. More specifically, 
the difference was mainly in their association rates (kon/nanodisc = 3.67 ×106 M-1·s-1, kon/detergent = 
7.34 ×105 M-1·s-1), while less so in their dissociation rates (koff/nanodisc = 0.76 ×10-2 s-1, koff/detergent = 
1.60 ×10-2 s-1). This resulted in different KD values, where nanodisc-solubilized A2AAR receptors 
displayed a KD value (1.98 nM) quite similar to those embedded in native membranes (KD = 0.93 
nM) as determined in radioligand binding assays. In comparison, the KD value for detergent 
solubilized receptors was 21.7 nM. Similar findings were shared by Cooke and colleagues from 
Heptares Therapeutics as well.65 In combination these studies demonstrate the influence of native 
membrane composition upon ligand-receptor interactions.54 
 
2.3. A2BAR 
Ligand-receptor binding kinetics at the A2BAR have been less investigated compared to the other 
AR subtypes. To date, most of the kinetic data for the A2BAR were obtained by using kinetic 
radioligand binding assays. Figure 5 has the chemical structures of representative A2BAR ligands 




Table 3. Binding kinetics of A2BAR ligands.  









MRS1754 HEK293hA2BAR membranes 25 2.2 × 107  0.027 1.2 122 
MRE2029-F20 CHOhA2BAR membranes 4 1.7 × 107 0.031 1.8 123 
OSIP339391 HEK293hA2BAR membranes 22 9.5 × 107 0.039 0.41 124 
Kinetic KD = koff/kon. 
 
N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl) -
phenoxy]acetamide (36, MRS1754) was the first selective A2BAR antagonist reported with 
binding kinetics (kon = 2.2 × 107 M-1∙min-1, koff = 0.027 min-1).122 Following this study, Baraldi 
and workers reported the synthesis and evaluation of a series of 8-heterocyclic substituted 
xanthine derivatives.125 This led to the development of N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-
1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide (37, 
MRE2029-F20) in a tritiated form. Its kinetics were determined on recombinant CHOhA2BAR 
cell membranes with an association rate of 1.7 × 107 M-1∙min-1 and a dissociation rate of 0.031 
min-1.123 Müller and colleagues also developed a xanthine derivative, namely 1-alkyl-8-
(piperazine-1-sulfonyl)phenylxanthine (38, PSB603), with kinetics similar to that of 
MRS1754.126 Other than the xanthine-like analogues, non-xanthine antagonists have been 
developed as well. One representative example is N-(2-{2-phenyl-6-[4-(3-phenylpropyl)-
piperazine-1-carbonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino}-ethyl)-acetamide (39, 
OSIP339391).124 Its binding kinetics on the A2BAR were in the same range of other A2BAR 
ligands, although OSIP339391 displayed a higher affinity (KD = 0.17 nM) than others 





Kinetic data for the A3AR are emerging. In Figure 6 the chemical structures of representative 
A3AR ligands are depicted. Their binding kinetics are in Table 4. 
 
Table 4. Binding kinetics of A3AR ligands.  







I-AB-MECA HEK293hA3AR membranes 37 6.1 × 107  0.042 0.69 127 
MRS5127 HEK293hA3AR membranes 25 2.4 × 108 0.51 2.1 128 
MRE3008F20 CHOhA3AR membranes 4 7.6 × 107 0.042 0.55 129 
Kinetic KD = koff/kon. 
 
2.4.1. A3AR receptor agonists 
The most widely used radioligand on the A3AR is the high-affinity agonist, 3-iodo-4-
aminobenzyl-5’-N-methylcarboxamidoadenosine (39, I-AB-MECA),130 first prepared in its 
radioiodinated form by Olah et al.131 The kinetics of [125I]-I-AB-MECA are relatively slow (kon = 
6.1 × 107 M-1∙min-1; koff = 0.042 min-1, 37 °C) compared to aforementioned agonistic radioligands 
on other AR subtypes.127 This is most likely due to its bulky aromatic substitution pattern at the 
N6 position of the adenine moiety, resembling the role of the phenyl moieties in UK432,097 on 
the A2AAR.  
Placing an aliphatic substitution on the C-2 position of the adenine core seems to yield 
compounds with slow kinetics too, as exemplified by the 2-substituted adenosine receptor 
agonist, 2-hexyn-1-yl-N6-methyladenosine (41, HEMADO). Its association at a concentration of 
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1 nM reached equilibrium between 30 min and 60 min, while its dissociation from the A3AR was 
complete in 60 min, all at room temperature.132  
In comparison, the radioiodinated (1′R,2′R,3′S,4′R,5′S)-4′-[2-chloro-6-(3-
iodobenzylamino)-purine]-2′,3′-O-dihydroxy-bicyclo-[3.1.0]hexane (42, MRS5127), reported by 
the Auchampach group, displayed much faster kinetics with association and dissociation both 
completed in less than 10 min (kon = 2.4 × 108 M-1∙min-1, koff = 0.51 min-1).128 Notably, the 5’-
hydroxylmethylene moiety in the ribose group is absent in MRS5127 and was replaced with a 
rigid N-methanocarba(bicyclo[3.1.0]hexane) ring system as a ribose substituent. This might be 
the structural basis for MRS5127’s shorter residence time, since the truncation at the 5’-position 
probably causes the loss of H-bond interactions with residues in the binding pocket—a key 
feature for long agonist-AR residence time, as demonstrated in the aforementioned A2AAR crystal 
structures25,27,108 and in the molecular dynamics study.109  
2.4.2. A3AR receptor antagonists 
A series of tricyclic imidazo[2,1-i]purinones derived from xanthine derivatives has been prepared 
with the aim of improving A3AR affinity.133 Among this series, 8-ethyl-4-methyl-2-phenyl-(8R)-
4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one (43, PSB-11) possesses high affinity for the 
hA3AR (Ki = 2.3 nM) and selectivity over other ARs. Kinetic characterization revealed this 
ligand quickly associates to and dissociates from CHOhA3AR cell membranes. Both processes 
were completed within 10 min.134 In another study, the Baraldi group reported a series of 
substituted pyrazolotriazolo pyrimidines as selective antagonists for the A3AR.135 N-[2-(2-
Furanyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N'-(4-
methoxyphenyl)urea (44, MRE3008F20) was one of a number of compounds showing high 
A3AR affinity (Ki = 0.29 nM). The kinetics of MRE3008F20 were determined in a kinetic 





The association rate constants of AR ligands vary substantially, across several orders-of-
magnitude. It had been assumed that target engagement is a diffusion-limited process by 
definition, with a corresponding rate constant for a ligand and a receptor encountering each other 
in the right stoichiometry and to form a binary complex.136,137 The data in Tables 1-4 demonstrate 
that this general assumption is not necessarily true. Most of the association rate constants are in 
the range well below the diffusion-limited value (about 6 × 109 ~ 6 × 1010 M-1∙min-1). 
Of note, the binding kinetics of orthosteric AR ligands summarized in Table 1-4 were 
obtained on varies species. Additionally, earlier kinetic studies were largely performed on tissue 
preparations rather than on membranes prepared from recombinant cell lines. These experimental 
variations could result in a different kinetic readout, which needs to be taken into account when 
comparing these data.  
The residence times of AR ligands also vary significantly, ranging from a few seconds to 
several minutes or hours, which might correspond to divergent biological effects. It is tempting to 
speculate whether long or short RT AR ligands are needed to direct future medicinal chemistry 
efforts. A ligand’s potential clinical indication as well as its on-target side effects should, 
therefore, be carefully considered. For instance, on the A3AR, acute or chronic treatment with the 
agonist IB-MECA induced paradoxical effects: the acute administration of the agonist to an in 
vivo gerbil model of global ischemia exacerbated histologic and functional damage, while chronic 
treatment of the same agonist over several weeks led to a highly neuroprotective, postischemic 
effect.138,139 Given these primary observations it might be useful to design long RT agonists for 
the A3AR. A2AR antagonists have been developed for the treatment of Parkinson’s disease (PD) in 
combination with dopaminergic therapies.140,141 A compound with a long receptor RT might be 
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preferred, since a sustained receptor occupancy can potentially reduce the wear-off effect of 
dopaminergic medications (e.g. levodopa) in between doses.141 Such information obtained from a 
kinetic perspective may provide additional rationales for the design of new AR ligands. 
 
3. THE INFLUENCE OF AN ALLOSTERIC MODULATOR ON THE ORTHOSTERIC 
LIGAND’S BINDING KINETICS 
ARs, as many GPCRs, can be allosterically modulated.14,15 However, a ‘pure’ modulating effect 
is rare for ARs (and other GPCRs), which is often “contaminated” with inhibition of the binding 
at the orthosteric site. Particularly in rhodopsin-like (class A) GPCRs the binding site for an 
allosteric modulator may be quite close to the orthosteric binding pocket, leading to the 
modulator also displaying activities as a competitor agonist/antagonist and decreasing the binding 
of the orthosteric ligand. Furthermore, an allosteric action to increase the binding of any 
adenosine remaining in e.g., membrane preparations may also contribute to a decrease in 
equilibrium radioligand binding. Given these complications, determining the binding kinetics, in 
particular the dissociation rate of an orthosteric ligand (or so-called “probe”) in the presence of an 
allosteric modulator has been used as an unambiguous measure of allosteric activity.142 In the 
following section, chemical classes of allosteric ligands and their structure-activity/kinetic 
relationships will be discussed. We will mainly focus on the allosteric effects on binding and 
kinetics of the orthosteric ligands unless mentioned otherwise. 
 
3.1. A1AR 
Chemical structures of representative A1AR allosteric modulators are represented in Figure 7. 




Table 5. Allosteric and antagonistic activities of A1AR allosteric modulators. 
Cmpd Allosteric effect EC50 (µM) a % antagonism b Ref. 
PD81,723 koff of [3H]-CCPA decreased 30%;  
AE score = 28% 
15 40 143,144 
46 122% enhancement c 6.0 32 145 
T-62 123% enhancement c 6.8 40 145 
LUF5484 151% enhancement c 6.2 35 145 
49 koff of [3H]-CCPA decreased 46% nd 4.8 143 
50 d AE score = 99%  nd 13 146 
51 d AE score = 91% 6.4 28 147 
54 e koff of [3H]-NECA decreased 52%  nd nd 148 
55 e koff of [3H]-NECA decreased 59% nd nd 149 
56 AE score = 57%  6.6 58 150 
57 AE score = 18%  2.1 82 150 
58 AE score = 77% 16 61 150 
59 AE score = 80% 1.4 9.2 144 
60 f AE score = 60% 14 23 151 
61 AE score = 74% 0.3 nd 152 
SCH202676 koff of [3H]-DPCPX decreased 69% nd -49 153 
LUF5794 koff of [3H]-DPCPX decreased 63% nd -32 153 
Amiloride g koff of [3H]-DPCPX decreased 46% nd nd 154 
HMA h koff of [3H]-DPCPX decreased 69% nd nd 154 
Data were obtained at 10 µM of test compounds on membranes of CHO cells expressing recombinant A1AR at 25 °C 
unless mentioned otherwise. AE scores were measured 10 min after the initiation of dissociation, and ranges from 0 
to 100%. A score of 100% means no dissociation and a score of zero means complete dissociation. nd, not 
determined. a EC50 for enhancing activity. b Orthosteric antagonistic activity, % inhibition of an orthosteric 
radioligand by 10 µM test compounds. Negative values indicated enhancement of radioligand binding. c Enhancing 
activity by test compounds expressed as percentage decrease in [3H]-CCPA dissociation over control (0%) and that of 
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10 µM PD81,723 (100%). Data were obtained on rat brain cortex membranes. d Data were obtained at 100 µM of the 
test compound. e Data were obtained at 1 µM of the test compound at 37 °C. f Data were obtained at 50 µM of the 
test compound. g Data were obtained at 1  mM of the test compound on rat forebrain membranes at 25 °C. h Data 
were obtained at 0.1  mM of the test compound on rat forebrain membranes at 25 °C 
 
The first AR allosteric ligand for the A1AR was reported by Bruns and Fergus in 1990.155 
Several compounds from a series of 2-amino-3-benzoylthiophenes, originally prepared as 
intermediates in the synthesis of benzodiazepine-like compounds156, were serendipitously 
discovered to possess an allosteric enhancing (AE) effect on the A1AR. These compounds were 
reported to increase the binding of the agonist radioligand [3H]-CHA to the A1AR in rat brain 
membranes and retard the dissociation of the radioligand, implying an allosteric mechanism of 
action. The compounds also behaved as competitive antagonists at the same receptor, since 
concentration-effect curves were bell-shaped with up to 45% stimulation of binding at 10 µM 
followed by inhibition at higher concentrations. Among these first-generation AR enhancers, 2-
amino-4,5-dimethyl-3-thienyl)-[3-(trifluromethyl)-phenyl]methanone (45, PD81,723) was found 
to be the most potent compound, displaying the best ratio of enhancement and antagonism in a 
following-up study from the same research group.142 Subsequently, PD81,723 has been 
investigated pharmacologically in greater detail by various research groups. It was convincingly 
demonstrated that PD81,723 also enhanced the preconditioning effect of endogenous adenosine 
in the heart, which proves the aforementioned concept of allosteric modulation.157 Furthermore, 
long-term exposure of cells expressing the human A1AR to PD81,723 induced only minor 
desensitization and down-regulation, which is encouraging in terms of therapeutic potential.158 
For these reasons, PD81,723 became the reference allosteric modulator of A1AR and many 
follow-up structure-activity relationship studies were performed.  
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3.1.1. 2-amino-3-substituted thiophenes 
Initial structure-activity relationships for enhancement of A1AR agonist binding (i.e. slowing the 
probe’s dissociation rate) by 2-amino-3-benzoylthiophenes were reported by Burns and 
coworkers.142 They concluded that the 2-amino group was essential as well as the carbonyl of the 
benzoyl moiety. Alkyl substitution at the 4-position of the thiophene ring augmented activity, as 
did substitutions on the phenyl ring, with the 3-trifluomethyl substituent showing optimal 
activity. 
Based on the initial SAR, van der Klein et al. modified the 4,5-dimethyl group and the 
substitution at the benzoyl moiety of PD81,723, yielding a series of compounds bearing 4,5-
dialkyl group superior to PD81,723 in terms of enhancing/antagonistic ratio.145 More specifically, 
(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(3-(trifluoromethyl)phenyl)methanone (46), 
(2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(4-chlorophenyl)methanone (47, T-62) and (2-
amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)(3,4-dichlorophenyl)methanone (48, LUF5484) 
showed significant enhancement (122%, 123% and 151% respectively) in [3H]-CPA dissociation 
experiments compared to PD81,723 (100%). Their antagonistic activity on the A1AR was 
comparable to that of PD81,723. From this study it was concluded that lipophilic benzoyl 
substitutions, such as 3-CF3 and 3,4-diCl, and thiophene 4-alkyl substitution favored AE activity, 
whereas bulky substitution at the 5-position favored antagonist properties. T-62 was later 
prepared in a tritiated form as the first radiolabeled A1AR allosteric enhancer by Baraldi group.159 
The biological evaluation of [3H]-T-62, although not very conclusive, suggested the presence of 
an allosteric binding site on the A1AR different from the binding site for orthosteric agonists and 
antagonists.   
The enhancing action of cycloalkyl-substituted thiophene derivatives was subsequently 
confirmed by Baraldi and coworkers.143 It was demonstrated that the cycloalkylthiophenes tended 
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to be more potent than their 4,5-dimethyl analogues. In addition to the chemical modification at 
the 4- and 5-positions of the thiophene moiety, the authors also varied the structures by replacing 
the original benzoyl moiety with a naphthoyl ring. This led to the discovery of (2-amino-4,5,6,7-
tetrahydrobenzo[b]thiophen-3-yl)(4-chloronaphthalen-1-yl)methanone (49), more potent than 
PD81,723 in slowing down the dissociation of [3H]-CCPA from CHOhA1AR cell membranes (i.e. 
koff decrease = 46% compared to 30% for PD81,723 at 10 µM). The inhibition activity of 49 at 10 
µM on the A1AR was modest as that of PD81,723. Furthermore, the allosteric effect of 49 was 
corroborated in a cAMP assay, in which forskolin-stimulated cAMP accumulation, challenged by 
CPA, was further decreased to 45%, similar to that of PD81,723 (50%). 
The initial SAR proposed by Bruns et al. was further extended and updated by Tranberg et 
al., who performed a systematic survey of the 2-amino-3-aroyl-4,5-alkylthiophenes 
derivatives.146 The authors specifically introduced polymethylene bridges of various length 
linking the 4 and 5-positions, in combination with divergent aromatic substitutions at the 3-
position. Compounds from aforementioned studies142,145 were also included to have a direct 
comparison of the AE activity. In this study, the AE score of different compounds was assayed as 
a decrease of the dissociation rate of 125I-ABA from the A1AR. GTPγS was specially introduced 
in the assay to speed up the dissociation of the radioligand, since in the absence of the nucleotide 
the dissociation of 125I-ABA was very slow (t1/2 ≈ 60 min). Briefly, compounds without 4- and 5-
substitutions had little or no AE activity. The same holds for the replacement of the 2-amino 
group with 2-carboxyl. Increasing the size of the thiophene C-4 and C-5 substituents significantly 
enhanced AE activity, which follows an ascending order of 4,5-diH, 4,5-diMe, cPent, cHex and 
cHep. With respect to C-3 position substitution, bulky (or hydrophobic) groups at the meta and 
para positions of the benzoyl group augmented AE activity. Replacing the 3-benzoyl group with 
a 3-naphthoyl group also had a favorable effect on the AE. Taken together, it is reasonable to 
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speculate that the allosteric binding site of the A1AR has ample space to accommodate 3-aroyl 
substituents that are bulky and/or hydrophobic but not necessarily planar; a second region of the 
binding pocket could interact with alkyl substituents at thiophene’s C-4 and/or C-5 positions. Of 
the tested compounds (2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-3-yl)(3-
methoxyphenyl)methanone (50) was discovered with the highest AE score (99%) while its 
inhibition of the antagonist radioligand [3H]-DPCPX was 13 %, much lower than that of 
PD81,723 (42%) at 100 µM. 
In a follow-up study, the same research group also tried 3,4- and 5-modifications at the 2-
amino-3-benzoylthiophene derivatives, including large space-filling groups, such as phenyl or 
substituted phenyl at the C-4 and/or C-5 positions.147 This generated various compounds with 
superior AE activity to that of PD81,723. The compound with the best AE score (91%) was [2-
amino-5-bromo-4-(3-trifluoromethylphenyl)thiophen-3-yl]phenylmethanone (51) and at 100 µM 
it displaced less [3H]-DPCPX (29%) compared to PD81,723 (85%). 
Substitutions at both C-4 and C-5 positions of thiophenes appear to have synergistic effects 
in enhancing the AE activity on the A1AR. To further study the role of the C4-position alone, a 
series of 2-amino-3-(p-chlorobenzoyl)thiophenes with different phenyl-substituted piperazine 
moieties attached to the C-4 part of the thiophene ring was prepared and biologically evaluated 
by the Baraldi group.160 The authors found that the nature of substituents on the phenyl ring 
tethered to the piperazine seem to exert a significant influence on the allosteric enhancer activity, 
with the 4-chlorophenyl analogue, (2-amino-4-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-5-
phenylthiophen-3-yl)(4-chlorophenyl)methanone (52),  and the 4-trifluoromethyl analogue, (2-
amino-5-phenyl-4-((4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)thiophen-3-yl)(4-




Encouraging results were found for 4-neopentyl substituted analogues as well.161 As a 
follow-up study, Baraldi and coworkers further examined the role of the C5-position on the AE 
activity in a second series of 4-neopentyl derivatives.148 The presence of an phenylacetylene at 
the 5-position of the thiophene proved optimal for activity. As evidence, even at a low 
concentration (1µM), (2-amino-4-neopentyl-5-(2-phenylethynyl)thiophen-3-yl)(4-
chlorophenyl)methanone (54) significantly retarded the dissociation of the agonist [3H]-NECA 
from the A1AR (control: koff = 0.016 min-1; + 54, koff = 0.0076 min-1), superior to that in the 
presence of PD81,723 at the same concentration (koff = 0.0143 min-1).  
Romagnoli et al. continued and extended the series of 2-amino-3-(p-
chlorobenzyl)thiophene to elaborate on the combined C-4 and C-5 positions of the scaffold.149 
They found that the allosteric contributions of phenyl and benzyl groups at these sites were 
clearly position dependent. Analogues with the phenyl group at the C-5 position and the benzyl 
group at the C-4 position were shown to be more efficacious than their corresponding 
regioisomeric 4-aryl-5-benzylthiophenes. In an SAR study, [2-amino-4-(4-chlorobenzyl)-5-(4-
chlorophenyl)-3-thienyl](4-chlorophenyl)methanone (55) showed the most prominent AE 
activity, significantly retarding the dissociation of [3H]-NECA from the A1AR (control: koff = 
0.019 min-1; + 55: koff = 0.0079 min-1). Compound 55 also showed a good anti-nociceptive effect 
in a formalin assay using a mouse model, confirming that allosteric enhancers at the A1AR could 
be useful in pain modulation. 
The structure-activity relationships at the C-5 position have also been extensively examined 
by Scammells and colleagues.150 The authors prepared two series of 5-substituted 2-amino-4-(3-
trifluoromethylphenyl)thiophenes. In the 3-ethoxycarbonyl series, ethyl 2-amino-5-(4-
chlorophenyl)-4-(3-trifluoromethylphenyl)thiophene-3-carboxylate (56) was the most potent and 
efficacious (EC50 = 6.6 µM, AE score = 57.0 %) in slowing down [125I]-ABA’s dissociation rate. 
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In the 3-benzoyl series, a series of 5-phenyl moieties with both electron-donating and -
withdrawing activity were prepared as well as an analogue without a C-5 substituent. It was 
found that  [2-amino-5-phenyl-4-(3-trifluoromethylphenyl)thiophen-3-yl]phenylmethanone (57) 
conferred the greatest AE potency (ED50 = 2.1 µM, AE score = 18%) but its counterpart with no 
5-substitution, i.e. [2-amino-4-(3-(trifluoromethyl)phenyl)thiophen-3-yl]phenylmethanone (58), 
proved to be most efficacious (ED50 = 16 µM, AE score = 77%). However, all compounds 
showed higher antagonist activity than PD81,723 in a [3H]-DPCPX competitive binding assay, 
evidence for their additional antagonist profile. 
Nikolakopoulos et al. studied three series of 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene 
and 2-amino-5,6,7,8-tetrahydrocyclohepta[b]thiophenes with 3-carboxylates and carboxamides as 
potential A1AR allosteric enhancers.144 A structure-activity relationship study of these compounds 
led to the discovery of 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid 
(59) with 80% AE activity, higher than 28% of PD81,723.  
Further optimization attempts were performed by introducing a fused ring to the thiophene 
core connecting the C-4 and the C-3 positions. Accordingly, a series of dihydrothieno[3,4-
d]pyridazines was synthesized and pharmacologically explored as new A1AR allosteric 
modulators.151 However, these compounds displayed potent orthosteric displacement, although all 
compounds from this series recognized the allosteric binding site on the A1AR, as revealed by an 
agonist radioligand kinetic dissociation assay. Ethyl 5-Amino-4-oxo-3-phenyl-3,4-
dihydrothieno[3,4-d]pyridazine-1-carboxylate (60) is an illustrative compound showing a good 
AE score (60%) and modest inhibition of [3H]-DPCPX binding (23%)  
3.1.2. 2-aminothiazoles  
2-Aminothiazoles represent another chemical class of allosteric modulators for the A1AR, firstly 
reported by Chordia et al.152 A SAR analysis of ligands from this series indicates that (1) tricyclic 
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2-aminothiazole derivatives are generally more AE active than their bicyclic counterparts, and 
among the tricyclic derivatives, compounds with the 6+5+5 ring system are more potent; (2) 
exchanging the positions of nitrogen and sulfur has a deleterious effect on the AE activity, 
suggesting an important role of the nitrogen for molecular recognition; (3) an electron-donating 
moiety on the aromatic ring improves AE activity. 2-Amino-3a,8a-dihydro-8H-indeno[1,2-
d]thiazol-7-yl acetate hydroiodide (61) was the most potent and efficacious compound in this 
series. 
A number of 2-aminothiazoles and their amide derivatives was also prepared in our lab. 
However, these compounds exerted little AE activity, in stark contrast to the abovementioned 
findings from Chordia et al.152 Interestingly, in a subsequent study Chordia et al. investigated 
these contrasting results and reconfirmed the AE activity of the 2-aminothiazoles. The authors 
suggested that one possible reason for the contradictory observations might be the different 
purification methods from two labs. Chordia et al. used 2-aminothiazole hydroiodide salts, 
whereas our lab prepared the free base form by base treatment of hydroiodide salts and 
purification by silica gel column chromatography. It was found that the free base variants of this 
type of compounds in freshly made solutions were only weak allosteric enhancers. However, the 
AE activity in solutions of these compounds in DMF, DMSO or acetonitrile increased after 4 h 
and finally led to a constant activity equivalent to that of the hydroiodide salts after 12 h.162 
Another putative factor complicating the interpretation of the different results might be the so-
called probe-dependency, that is, the extent of allosteric action depending on the nature of the 
orthosteric ligand.163,164 Notably, the assessment of AE activity of the 2-aminothiazoles was 
undertaken with different orthosteric radioligands (i.e. [3H]-CCPA and 125I-ABA) in different 
labs. Given this, it might be interesting to further examine the same compound prepared in the 
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same form (free base or hydroiodide salt) using the same radioligand to confirm the AE profile of 
the 2-aminothiazoles. 
3.1.3 Thiadiazoles as putative allosteric modulators.  
Several ligands have been reported as promiscuous modulators for GPCRs. One exemplary case 
is N-(2,3-diphenyl-1,2,4-thiadiazol-5(2H)-ylidene)methanamine (62, SCH202676). It has been 
shown to interact with many GPCRs, including opioid, muscarinic, adrenergic and dopaminergic 
receptors.165 The allosteric modulating effect of SCH-2022676 on the ARs was examined in our 
lab, along with a series of newly prepared thiadiazoles with varied substitutions at the 2-, 3- and 
5-positions. SCH-2022676 and 5-N-methylimino-2-(4-methoxyphenyl)-3-phenyl-2H-
[1,2,4]thiadiazole (63, LUF5794) strongly decreased the dissociation rate of [3H]-DPCPX (from 
0.35 min-1 to 0.11 min-1 and 0.13 min-1, respectively), thereby resulting in a prolonged t1/2 value 
for the dissociation process. The apparent KD of [3H]-DPCPX in the presence of LUF5794 was 
slightly increased, indicating its role as an enhancer of antagonist binding to the A1AR.153 
However, a follow-up study from our lab showed that thiadiazoles are sulfhydryl modifying 
agents rather than allosteric modulators as they appear to reversibly modify the sulfhydryl groups 
of cysteine residues in cell membrane preparations.166 This general feature explains their non-
selective modulating effect on GPCR binding and functioning. A similar mechanism was 
suggested for 1,2,4-thiadiazoles acting as cathepsin B inhibitors167 or melanocortin MC4 receptor 
agonists168.  
3.1.4. Non-selective allosteric modulators.  
An allosteric regulation of ligand binding by sodium ions was observed on the A1AR as well as 
for GPCRs from other subfamilies such as dopamine D2,169 opioid,170 or α-adrenergic 
receptors,171 among others.38 At high-salt concentrations, agonist affinity for the receptor 
decreased one order of magnitude. The effect occurred through the binding of Na+ at the 
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Asp552.50 site. As evidence receptor agonist affinity did not change over a range of sodium ion 
concentrations from 0-400 mM when the residue was mutated to Asp55Ala2.50.38 
Amiloride (64), a potassium-sparing diuretic drug, is also acting as a promiscuous agent for 
many GPCRs,171-173 including the AR. The action of the compound was initially postulated to be 
linked to its known action of inhibiting Na+ transporter systems.174,175 However, on the A1AR the 
addition of NaCl (145 mM) enhanced the maximal binding capacity of [3H]-DPCPX, which was 
against the inhibitory effect of [3H]-DPCPX binding in the presence of amiloride. Additionally, 
the relationship between the structure of amiloride analogues and their affinity for the A1AR 
differed from the known SAR for the Na+/H+ exchange/transporter system. These results thus 
excluded the involvement of the Na+/H+ exchange system.176 Amiloride increased the dissociation 
rate constant of [3H]-DPCPX significantly (control, koff = 0.13 min-1; + 1 mM amiloride, koff = 
0.19 min-1). However, at the same concentration amiloride displayed no effect on the dissociation 
rate constant of the agonist radioligand [3H]-R-PIA. Similarly, 5-(N,N-hexamethylene)amiloride 
(65, HMA), an amiloride analogue, showed a negative allosteric effect on the dissociation of 
[3H]-DPCPX from the A1AR (control, koff = 0.13 min-1; + 0.1 mM HMA, koff = 0.22 min-1) while 
not so on [3H]-R-PIA.154 
3.1.5. Binding sites for A1AR allosteric modulators 
Probing the binding site for an allosteric modulator is difficult, since residues at the allosteric site 
in GPCRs are supposed to be less conserved among family subtypes. Although the 
crystallographic structure of the M2 muscarinic receptor simultaneously bound to the orthosteric 
agonist iperoxo and the positive allosteric modulator LY2119620 has been recently been 
elucidated177, still little is known about the possible molecular mechanism of allosteric 
modulation at other GPCRs.178 To date, in the absence of structural information, the exact 
location of the allosteric site on the A1AR remains unknown.  
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Since most of the allosteric modulators on the A1AR showed mixed profiles of orthosteric 
antagonist as well as allosteric modulator, several lines of research suggest that the allosteric site 
might be in the proximity of the orthosteric site. Such speculation was corroborated by probing 
the allosteric site using a series of bitopic ligands with an increasing linker length between the 
orthosteric and allosteric pharmacophores. Both functional and kinetic investigations of these 
compounds, further discussed below in Section 4, suggested that the compound with a nine 
carbon atom spacer can simultaneously bridge both binding sites.57,179 This narrows down the 
putative region of the allosteric site within the boundary of the second extracellular loop (ECL2) 
of the receptor. In another study, Peeters et al. performed an alanine scan on both ECL2 and 
ECL3 to investigate the influence on the allosteric effect of PD81,723. The result highlighted the 
role of Try156ECL2 and Glu164ECL2, as demonstrated by the significantly affected modulating 
effect of PD81,723 on the binding and function of CPA at the Ala mutant of both residues.180 
Taken together, these studies provided useful information increasing our understanding of the 
molecular aspects of allosteric modulation at the A1AR. 
 
Table 6. Allosteric activities of A2AAR allosteric modulators. 
Cmpd Allosteric effect a Ref. 
Sodium ions b -38%  181 
HMA c  12-fold 181 
Amiloride c 1.2-fold  181 
66 d -37%  182 
ZB1854 e -31% 183 
a Expressed as the influence on dissociation rate of [3H]-ZM241385 from the A2AAR. Positive and negative values 
indicate increasing or decreasing dissociation rates, respectively. b Data were obtained at 100 mM of the test 
compound on rat striatal membranes at 25 °C. c Data were obtained at 1 mM of the test compound on rat striatal 
membranes at 4 °C. d Data were obtained at 10 µM of the test compound on membranes of CHO cells expressing 
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recombinant human A2AAR at 0 °C. e Data were obtained at 2 mM of the test compound on membranes of HEK293 
cells expressing recombinant human A2AAR at 4 °C. 
 
3.2. A2AAR 
Chemical structures of representative A2AAR allosteric modulators are depicted in Figure 8. The 
allosteric activity of these compounds is summarized in Table 6.  
3.2.1. Non-selective allosteric modulators.  
The allosteric effect of sodium ions has been described for the A2AAR as well.181 The binding of 
sodium ions stabilizes an inactive conformation of the A2AAR, suggested by both the high-
resolution A2AAR/ZM241385 crystal structure and several molecular dynamics simulations 
studies based thereon.32,184,185 The dissociation rate of [3H]-ZM241385 was significantly 
decreased from 0.24 min-1 to 0.15 min-1 in the presence of Na+ at a physiological 
concentration.181 In comparison, the binding of agonist and Na+ appears to require mutually 
exclusive conformational states of the A2AAR.184  
Amiloride (64) and analogues have also been tested on the A2AAR, where they increased 
the off-rate of [3H]-ZM241385 from the A2AAR. Among the derivatives HMA (65) proved to be 
the most potent allosteric inhibitor.181 It produced a 12-fold enhancement of the off-rate of 
ZM241385 compared to the 1.2-fold enhancement by amiloride at the same concentration. 
3.2.2. Emerging selective allosteric modulators 
The first selective allosteric modulator of the A2AAR was developed by Giorgi et al.182 1-[4-(3-
Benzyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ylamino)-phenyl]-3-(4-fluorophenyl)-urea 
(66) proved to be the most promising compound amongst the series of purine- and 8-azapurine-
N6-1,3-diphenylurea derivatives. It was observed that 66 at 10 µM increased the specific binding 
of both [3H]-ZM241385 and [3H]-CGS21680 in an equilibrium binding assay, and retarded the 
dissociation rate of [3H]-ZM241385 from the A2AAR (control, koff = 0.082 min-1; + 66, koff = 
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0.052 min-1). Kinetics for the agonist radioligand were not reported, but further characterization 
of 66 in a functional study showed the compound was able to potentiate the A2AAR-mediated 
action of vasorelaxing responses by CGS21680 in rat aortic rings precontracted by the adrenergic 
agonist noradrenaline. These results suggest 66 could be a lead for developing new allosteric 
modulators for the A2AAR, although it is somewhat surprising that both agonist and antagonist 
seemed to be modulated in a similar way.182 
Recently, Siegal and coworkers reported on a fragment screening campaign on the A2AAR 
using biophysical methods to identify A2AAR ligands with allosteric modulatory activity.183 The 
authors used an approach called target immobilized NMR screening (TINS),186 in which a target 
and reference protein are immobilized on a compatible solid support; binding of fragments to the 
immobilized protein can be detected by fluctuations in the 1D 1H NMR spectrum of a 
ligand.187,188 This approach was in combination with an antagonist-stabilized A2AAR to overcome 
the instability and fragility of GPCRs during these time consuming experiments.189,190 Since 
TINS selects for fragments that bind to the target regardless of binding sites, hits from the screen 
were then thoroughly characterized in follow-up binding and second messenger assays. Several 
hits were found with promising allosteric modulating profiles when tested in a kinetic radioligand 
dissociation assay using [3H]-ZM241385 and [3H]-NECA. As a result, three of 94 fragment hits 
were identified with significantly (at least 30%) increased koff of the orthosteric ligand (negative 
allosteric modulators), and four with significantly decreased koff (positive allosteric modulators). 
In addition, another four fragments allosterically enhanced either [3H]-NECA or [3H]-ZM241385 
binding. One exemplary hit with detailed characterization is 3-(3,4-dihydroquinolin-1(2H)-
yl)propanoic acid (67, ZB1854). It showed a concentration-dependent modulatory effect on the 
dissociation of [3H]-ZM241385 from the A2AAR (control, koff = 0.0121 min-1; + 0.5 mM ZB1854, 
koff = 0.0102 min-1; + 1 mM ZB1854, koff = 0.0072 min-1; + 2 mM ZB1854, koff = 0.0058 min-1). 
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In a cAMP assay ZB1854 potentiated the maximal effect (Emax) of CGS21680. This was 
consistent with the data from the kinetic radioligand binding experiment, suggesting ZB1854 acts 
via an allosteric mechanism.164,191 It will be interesting to evolve the identified low potency 
fragment hits to lead-like compounds as novel A2AAR allosteric modulators. 
3.2.3. Binding sites for A2AAR allosteric modulators 
Recent advances in structural biological have greatly improved our knowledge of ligand-receptor 
interactions. The A2AAR represents one of the most successful examples with several crystal 
structures available. In particular, the recently elucidated high-resolution structure of the A2AAR 
in complex with the antagonist ZM241385 unveiled the binding site for sodium ions. It was 
observed that the positively charged ion has a direct interaction with the highly conserved 
aspartate residue Asp522.50, harbored in a cluster of structural water molecules.32 Mutating 
Asp522.50 to either asparagine or alanine reduced or abrogated the allosteric effect of sodium ions 
on the A2AAR and other GPCRs as well.184 Furthermore, results from molecular dynamics 
simulations suggested Asp52A2.50 directly affected the mobility of sodium ions, which readily 
migrated to another pocket formed by Glu131.39 and His2787.43.185 Amiloride and derivatives were 
shown to compete with sodium ions for the same binding site.181 As evidence, the Asp52A2.50 
mutant also decreased the potency of amiloride with respect to ligand displacement but did not 
change orthosteric ligand affinity. Notably, the binding site for sodium ions and amiloride is deep 
in the 7TM cavity, different from the proposed or demonstrated site for other allosteric 
modulators on top of the binding cavity near the extracellular loops on other GPCRs such as the 
muscarinic receptors111,192 or β2 adrenergic receptor110. It is possible that several allosteric binding 
sites coexist on the A2AAR, as reported in e.g., the gonadotropin-releasing hormone (GnRH) 
receptor.173 One is conserved for non-selective allosteric modulators, such as sodium ions and 
45 
 
amiloride, to universally ‘lock’ the receptor in a ground, inactive state, while others are more 
diversely located, responsible for specific A2AAR-mediated effects. 
 
3.3. A2BAR 
The A2BAR is the least characterized subtype in the AR family, partly due to the late availability 
of selective (radio-)ligands. Only one series of 1-benzyl-3-ketoindole derivatives as allosteric 
modulators for the A2BAR has been reported, although originally designed as potential AR 
antagonists (Figure 9). Some of these compounds were shown to be putative allosteric 
modulators for the A2BAR in a cAMP assay.193 This was later confirmed in a follow-up study with 
detailed biological evaluations.194 Interestingly, compounds from the same chemical class acted 
differently, showing either negative or positive allosteric modulating effects. In the presence of 2-
(1-benzyl-1H-indol-3-yl)-2-oxo-N-phenylacetamide (68) the dissociation of [3H]-NECA was 
slowed down from 0.0162 min-1 to 0.0086 min-1, indicating a positive modulation of A2BAR. In 
contrast, the presence of 1-benzyl-N-phenyl-1H-indole-3-carboxamide (69) increased the 
dissociation of [3H]-NECA to 0.0481 min-1, consistent with a typical profile of a negative 
allosteric modulator. Furthermore, in functional assays 68 increased agonist efficacy without 
changing its potency, whereas 69 reduced agonist potency and efficacy. Thus, these compounds 
may serve as leads for the discovery of other allosteric modulators for the A2BAR. 
 
3.4. A3AR 
Chemical structures of representative A3AR allosteric modulators are represented in Figure 10. 
The allosteric activity of these compounds is summarized in Table 7.  




Table 7. Allosteric and antagonistic activities of A3AR allosteric modulators. 
Cmpd Allosteric effect  Ki (µM) or % displ. at 10 µM Ref. 
VUF5455 koff of [125I]-I-AB-MECA was decreased 43% a 1.7 127 
LUF6096 249% enhancement b 17% 195 
DU124183 koff of [125I]-I-AB-MECA was decreased 46% 0.82 196 
LUF6000 173% enhancement c 45% 197 
74 196% enhancement d 17% 198 
2-AG koff of [125I]-I-AB-MECA was decreased 58% 0.79 199 
HMA e koff of [125I]-I-AB-MECA was decreased 47%; 
koff of [3H]-PSB-11 was increased 1.6-fold 
5.7 f 154 
Data were obtained at 10 µM of test compounds on membranes of CHO cells expressing recombinant human A3AR 
at 25 °C unless mentioned otherwise. a Data were obtained on membranes of HEK293 cells expressing human A3AR 
at 37 °C. b Expressed as % of [125I]-I-AB-MECA dissociation at 120 min, control = 100%. c Expressed as % of [125I]-
I-AB-MECA dissociation at 30 min, control = 100%. d Expressed as % of [125I]-I-AB-MECA dissociation at 60 min, 
control = 100%. e Data were obtained at 100 µM of the test compound. f IC50 value (µM) displacing [3H]-PSB-11 
from the A3AR. 
 
In 2001, Gao et al. reported on a series of 3-(2-pyridinyl)isoquinoline derivatives as the first 
selective allosteric modulators for the A3AR.127 Interestingly, this series of ligands was originally 
identified as potential antagonists for the A3AR.200 By examining their effects on the dissociation 
rate of the agonist radioligand, [125I]-I-AB-MECA, from the A3AR,  the authors found that 4-
methoxy-N-[7-methyl-3-(2-pyridinyl)-1-isoquinolinyl]benzamide (70, VUF5455) significantly 
retarded the dissociation rate of the radioligand in a concentration-dependent manner, consistent 
with a typical profile of an allosteric enhancer. Its effect on the dissociation rate of the antagonist 
[3H]-PSB-11, however, was insignificant, suggesting VUF5455 was a selective enhancer of 
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agonist binding. In competitive binding studies VUF5455 displayed modest displacement of the 
orthosteric ligand (Ki = 1680 nM). Its analogue without 7-methyl substitution (VUF8504), 
however, showed little effect on the allosteric activity. Instead, the A3AR affinity was increased 
(Ki = 17.3 nM). Furthermore, chemical modifications of the 4’-methoxy group of VUF8504 
lowered its competitive binding affinity without a major loss of the AE effect. A similar effect 
was observed when the carboxamido group was replaced for an  imino group. Taken together, it 
is tempting to speculate that further chemical modifications at the aforementioned positions 
might lead to a further separation of the orthosteric and allosteric actions on the A3AR. 
A series of 2,4-disubstituted quinolines was synthesized and evaluated as a new class of 
allosteric enhancers of the A3AR.195 Among these compounds, N-{2-[(3,4-
dichlorophenyl)amino]quinolin-4-yl}cyclohexanecarboxamide (71, LUF6096) was the most 
potent enhancer. It was able to change the biphasic dissociation of [125I]-I-AB-MECA from the 
receptor into a monophasic process, from the result of slowing down the agonist’s kinetics in the 
fast dissociating phase (koff_fast = 0.089 min-1 to 0.035 min-1). This phenomenon suggests that 
LUF6096 can specifically stabilize the active conformation of the receptor. This is also supported 
by data from a functional assay, in which LUF6096 significantly enhanced the intrinsic activity of 
Cl-IB-MECA to 286% (control = 100%). In the absence of the orthosteric ligand, no inhibition of 
forskolin-induced cAMP production was observed, suggesting a “clean” profile of allosteric 
modulation. LUF6096 also displayed high target selectivity. As evidence, no enhancement was 
observed on the A1AR. Additionally, negligible orthosteric competition on the four AR subtypes 
was shown for LUF6096. 
3.4.2. Imidazoquinoline derivatives 
Similar to the discovery of the isoquinoline derivatives, imidazoquinolines were originally 
defined as non-xanthine AR antagonists as well.201 Later pharmacological characterization of 
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these compounds revealed their allosteric enhancer profile for the A3AR.196 2-Cyclopentyl-N-
phenyl-1H-imidazo[4,5-c]quinolin-4-amine (72, DU124183) was the most potent compound 
from this series, and selectively enhanced agonist binding and function at the A3AR. As evidence, 
DU124183 decreased the dissociation rate of the agonist [125I]-I-AB-MECA from the A3AR 
(control: koff = 0.056 min-1; + DU124183, koff = 0.030 min-1) but not for the antagonist [3H]-PSB-
11, or for [3H]-R-PIA on the A1AR and [3H]-CGS21680 on the A2AAR.  
In a follow-up study, structural modifications were performed by Göblyös et al. at the 4- 
amino and 2-position of DU124183.197 This effort led to the discovery of 2-cyclohexyl-N-(3,4-
dichlorophenyl)-1H-imidazo[4,5-c]quinolin-4-amine (73, LUF6000), which enhanced agonist 
efficacy in a functional assay and decreased the agonist dissociation rate without influencing 
agonist potency. Surprisingly, LUF6000 was even able to convert an antagonist into an agonist on 
the A3AR, representing a novel mechanism of GPCR activation. 202 
Further synthetic attempts on the imidazoquinoline derivatives were reported by Kim et 
al..198 The authors introduced divergent structural changes at the 2- and 4-positions of the 
scaffold. Only few substituents at these positions were tolerated to preserve the AE activity on the 
A3AR. N-(3,4-dichlorophenyl)-2-(1-adamantanyl)-1H-imidazo[4,5-c]quinolin-4-amine (74) with 
a bulky adamantanyl group at the 2-position displayed an comparable AE activity to that of 
LUF6000 and yet minimal inhibition of orthosteric binding on the A3AR. This study showed that 
allosteric and orthosteric inhibitory effects in the imidazoquinolines series are structurally 
separable. 
3.4.3. Non-selective allosteric modulators 
Compounds from different sources have also been reported with allosteric actions on the A3AR. 
For instance, Lane et al. found that the endogenous cannabinoid agonist 2-arachidonylglycerol 
(75, 2-AG) was able to accelerate the dissociation of [125I]-I-AB-MECA from the A3AR, 
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consistent with an action as a negative allosteric modulator.199 The same holds for amiloride 
analogues, a finding supported by data from both binding and functional assays.154 HMA was the 
most potent compound, which significantly increased the dissociation rate of [3H]-PSB-11 
(control: koff = 0.007 min-1; + 100 µM HMA: koff = 0.016 min-1). In contrast, HMA displayed a 
positive modulatory effect on the dissociation rate of an agonist radioligand, [125I]-I-AB-MECA, 
retarding its dissociation rate from 0.059 min-1 to 0.031 min-1. 
3.4.4. Binding site for A3AR allosteric modulators 
Several residues responsible for the allosteric modulation of the A3AR have been identified by 
Gao et al..203 These residues include Phe1825.43 and Asn2747.45 . Upon mutation of both residues 
to alanine DU124183 and VUF5455 lost their allosteric effects. However, the binding of the 
orthosteric agonist was not affected. The Asp1073.49Asn mutant abolished the effects of 
DU124183, but not of VUF5455. In another study, Deganutti et al. used Supervised Molecular 
Dynamics (SuMD)204, a computational  method for the acquisition of the ligand-receptor 
recognition trajectory, to delineate the molecular mechanism of LUF6000’s activity.178 The 
authors suggested two possible mechanisms by which LUF6000 might exert its positive allosteric 
modulator effect. One is involving conformational changes in ECL2 triggered by LUF6000 that 
enables adenosine to form more energetically favorable interactions with the residues located 
deeper in the orthosteric binding site. Another possibility is that LUF6000 forms a ternary 
complex with the agonist and the receptor and thus acts as a cap for the orthosteric binding 
pocket. It was also noticeable that during the simulations LUF6000 was able to establish 
favorable interactions with conserved residues in the orthosteric binding site of the A3AR, 
consistent with the experimentally observed modest orthosteric competition profile of the 





Extensive structure activity relationship studies of allosteric modulators have been performed on 
the A1AR and A3AR, yielding novel chemical entities with convincing allosteric effects.  On the 
A1AR, the 2-amino-3-substituted thiophene scaffold is the most studied, whereas on the A3AR 
isoquinoline and quinoline derivatives as well as imidazoquinoline derivatives have promising 
allosteric actions. In comparison, fewer studies and less convincing results have been reported on 
the A2AAR and A2BAR.  
 
4. BINDING KINETICS OF BITOPIC LIGANDS 
Recent studies have begun to explore the possibilities of linking orthosteric and allosteric 
pharmacophores to yield so-called “bitopic” ligands, or dualsteric/bivalent ligands in other 
terms.20,205 Through concomitant engagement with both orthosteric and allosteric sites on a single 
target, the bitopic ligand may offer several advantages over the classical ‘monovalent’ ligand.205 
Firstly, it can show improved subtype selectivity, as exemplified by several bitopic ligands on the 
muscarinic receptors, when compared to non-selective orthosteric agonists for the different 
receptor subtypes.206-209 Secondly, a bitopic ligand can promote biased signaling and hence cause 
the separation of on-target efficacy from adverse effects. An example is the A1AR bitopic ligand 
VCP746 (Figure 11, 76), which displayed biased agonism relative to prototypical A1AR ligands 
in native rodent cells and isolated rat atria.210 Additionally, bitopic ligands are good tool 
compounds for understanding the spatial geometry within the ligand-GPCR complex. For 
instance, Narlawar et al. designed a series of A1AR bitopic ligands containing linkers with 
varying lengths to probe the distance between the orthosteric and allosteric binding sites.179  
The special pharmacological profile of a bitopic ligand, as mentioned above, may be 
reflected in its unique binding kinetics. Notably, upon binding, each pharmacophore has its own 
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“micro-” binding kinetics that can induce synergistic effects (i.e. allosteric cooperativity) on the 
overall apparent kinetics of the compound—greater than simply combining two monovalent 
ligands.211-213 More specifically, a dissociating allosteric or orthosteric pharmacophore of a 
bitopic ligand is obliged to remain in “forced proximity” to its cognate binding site—instead of 
dissociating further away—as long as the tethered, companion pharmacophore is still bound.212 
This favors its rebinding to that site, thereby significantly retarding the net dissociation process of 
the bitopic ligand.214 As evidence, two A1AR bitopic ligands (Figure 11), LUF6234 (77) and 
LUF6258 (78), exerted significantly increased receptor residence times compared to the 
monovalent parent orthosteric ligand LUF5519 either in the absence or presence of the allosteric 
modulator PD81,723.57  
 
5. FUTURE PERSPECTIVES AND CHALLENGES FOR KINETIC CHARACTERIZATIONS 
5.1. Structure-kinetics relationship (SKR) and structure-activity relationship (SAR) studies 
SKR and SAR studies of orthosteric AR ligands are emerging, particularly for the A1AR and 
A2AAR.72,73,106 Apparently, ligands in the same chemical series with similar affinities can display 
divergent binding kinetics. Such detailed SKR studies offer added value to the traditional metric 
of affinity. This is exemplified by LUF6632 (32), a high-affinity A2AR ligand previously reported 
by Vu et al. (compound 11 in the original paper).118 Further subjecting this compound to a kinetic 
characterization revealed its exceptional long RT (323 min). This type of information can support 
the selection of LUF6632 from its analogues with similar affinity for further testing. Similarly on 
the A1AR, capadenoson (13) showed a RT of 28 min while its analogue LUF6941 (14) displayed 
a RT of 132 min. Both compounds have high affinity on the A1AR (capadenoson, 1.4 nM; 
LUF6941, 5.0 nM). If affinity were the only factor taken into consideration, LUF6941 would not 
be selected among capadenoson and other analogues with better affinity. Now with its kinetic 
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results determined, LUF6941 may be an interesting candidate for further in vivo testing as well. 
Thus, the strategy combining both SAR and SKR provides a better understanding of a 
compound’s molecular mechanism of action. It includes detailed characterization of not only the 
bound states under equilibrium (SAR) but also the entire ligand-receptor interaction that 
comprises metastable intermediate states and transition states (SKR).215 Such knowledge may 
offer new rationales for efficient drug design and yield improved drug candiates.45 
 
5.2. Signaling bias and ligand-receptor binding kinetics 
GPCRs are pleiotropic with respect to the signaling protein to which they couple in a cell. It is 
now widely accepted that agonists of GPCRs do not uniformly activate all cellular signaling 
pathways linked to a given receptor—a phenomenon termed signaling bias.216 “Biased” ligands – 
ligands that selectively activate one pathway over another –  are therapeutically tempting, since 
they may deliver more precise therapeutic benefits with fewer side effects than current drugs.217 
This is exemplified by the biased opioid receptor agonists which might provide pain relief 
without the adverse side effects normally associated with the opiate narcotics, presumably due to 
the activation of the µ-opioid receptor rather than recruiting of the arrestins.218 Studies probing 
biased signaling on the ARs are emerging as well.219 The differential effects in various signaling 
pathways can be induced by an orthosteric ligand,220 an allosteric modulator,221 or more recently 
a bitopic ligand.210 It has been proposed that these ligands exert their effects through stabilization 
of unique active receptor states to create a signal that is “biased” towards specific cellular 
pathways.216,222  Such stabilization of different receptor states is likely caused by differences in 
strength of interaction between the receptor and a given ligand, hence linking with different 
binding kinetics. In this sense, slow binding kinetics might be diagnostic of conformational 
changes, as exemplified by maraviroc’s long residence time at the CCR5, where reorganizations 
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of the initial maraviroc-receptor complex were involved.223 Alternatively, different ligand-
receptor binding kinetics might drive the stabilization of specific receptor states acting on varied 
downstream signaling pathways.  
 
5.3. Equilibrium selectivity and kinetic selectivity profiling  
An exploration of ligand binding kinetics at different targets will also help in selectivity profiling. 
This is complementary to the classical equilibrium selectivity profiling, i.e., determining the 
affinity of lead compounds against a number of potential targets under equilibrium conditions. 
Combining both aspects of selectivity profiling may ‘‘rescue” many potent yet nonselective 
compounds, increasing the number of potential candidate drugs moving to clinical trials and 
finally to the market. This is particularly useful in cases in which its ‘equilibrium selectivity’ is 
less than ideal. A study was recently reported in the context of adenosine receptors. The 
equilibrium Ki values and binding kinetics of six AR antagonists were examined on three 
adenosine receptors, namely A1AR, A2AAR and A3AR.224 It was found that XAC and 2,6-
diphenyl-8-propyl-9H-purine (79, LUF5964, Figure 6) were kinetically more selective for the 
A1AR and A3AR, respectively, although they are non-selective in terms of their affinity. In 
comparison, 6-phenyl-2-(p-tolyl)-9H-purine (80, LUF5967, Figure 3) displayed a strong 
equilibrium-based selectivity for the A1AR over the A2AAR, yet its kinetic selectivity thereon was 
less pronounced. This study provides evidence that equilibrium and kinetic selectivity profiling 
can both be important in the early phases of the drug discovery process. The combined strategy 
could be considered for future medicinal chemistry efforts and aid the design and discovery of 




5.4. Measuring the binding kinetics of allosteric modulators 
Knowledge of the kinetics of an allosteric modulator interacting with its cognate binding site on 
the AR would allow us to compare an allosteric modulator’s binding kinetics with its modulating 
effect. It is tempting to speculate that a long RT allosteric modulator might be able to trigger a 
more profound modulatory effect than a short RT ligand can do. However, due to practical issues 
such as their relatively low, micromolar potency, data for AR allosteric modulators are yet to be 
determined. The availability of one radiolabeled A1AR allosteric modulator, [3H]-T-62, suggests 
the use of it in kinetic radioligand binding assays. However, its low affinity (KD = 4.6 μM) most 
likely precluded such experiments. High affinity allosteric modulators are therefore highly 
desired. An alternative approach may be SPR technology, as it worked in the kinetic 
characterization of low-affinity orthosteric A2AAR ligands.65 Another possibility may be to follow 
the BRET signal over time of a fluorescently labeled allosteric modulator in living cells in 
combination with a bioluminescent target, as demonstrated by Stoddart et al. to monitor ligand 
binding to a GPCR225. Needless to say that extensive assay optimizations are needed for both 
technologies to enable robust kinetic measurements of AR allosteric modulators. 
 
5.5. Molecular mapping of the binding site for allosteric modulators 
Molecular mapping of the allosteric binding site on the ARs is challenging. Although several 
mutagenesis studies have shed light on several functionally important residues in maintaining an 
AR allosteric modulating effect, there is still no direct evidence confirming these residues are 
interacting with the allosteric modulator. The bitopic ligands represent good tools to probe the 
allosteric binding site, however, due to the inherent flexibility of the linker and the lack of further 
structural information any conclusion where the allosteric pharmacophore binds remains 
speculative. Receptor crystallography in the presence of an allosteric modulator provides the 
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most direct structural evidence for the binding site. One example is the elucidation of the human 
M2 muscarinic acetylcholine receptor structure in complex with both an orthosteric ligand, 
iperoxo, and an allosteric modulator, LY2119620.177 As shown in Figure 12, the modulator is 
accommodated above the orthosteric ligand, engaging in extensive interactions with the 
extracellular vestibule including an aromatic stacking with Tyr177ECL2 and Trp4227.35 as well as 
several polar interactions with Tyr802.61, Asn4106.58, Asn419ECL3 and Glu172ECL2. This allosteric 
binding site is directly superficial to the cognate orthosteric site, separated by a tyrosine lid, with 
Tyr4267.29 interacting with both ligands. Reasoning from here, structure-based molecular 
dynamics simulations may provide a “computational microscope” to visualize the dynamic 
ligand-receptor interaction.111,226 With recent advancements in structural biology, increased 
computational power and dedicated software, we envision that the location of allosteric sites on  
ARs can be unveiled in the near future. 
 
5.6. Characterization of ligand-receptor binding kinetics in living cells 
Characterization of ligand-receptor binding kinetics in living cells is of great interest and is 
essential to bridge the gap between the binding kinetics in vitro to the pharmacological response 
in vivo. However, the assay readout for the ARs is often complicated. For accurate data 
interpretation one should take into account several issues.  
Firstly, it is now generally accepted that ARs can form homo- or heterodimers and thereby 
influence the kinetics of the ligand-receptor interaction. This is well illustrated by several studies 
on the A3AR by Hill and colleagues. One example is the measurement of the dissociation kinetics 
of ABA-X-BY630 from the A3AR.64,227 In the absence of a competitive ligand its koff value was 
0.57 min-1. This value was significantly increased by both orthosteric antagonist and agonist 
(antagonist, XAC: 15-fold; agonists, NECA: 9-fold and adenosine: 19-fold)—an observation not 
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compatible with that of a GPCR existing as monomer. The authors suggested that the kinetics of a 
ligand binding to one protomer can be modulated through negative cooperativity by targeting a 
binding site within the second, interacting protomer. Supporting this assumption, the effect was 
decreased when coexpressing a ‘nonbinding’ A3AR mutant (Asn2506.55Ala). Homodimerization 
of A1ARs seems to occur as well at the surface of living cells, yet the extent of cooperative 
interactions was less pronounced than for the A3AR. AR heterodimerization has also been 
observed and documented, e.g., between adenosine A1AR and dopamine D1R and between 
adenosine A2AAR and dopamine D2R in the central nervous system.228 Franco and coworkers 
have shown that selective A1AR agonists negatively affect the high affinity binding of D1R. 
Likewise, activation of A2AAR led to a decrease in receptor affinity for dopamine agonists acting 
on D2R, specifically of the high-affinity state. These interactions have been reproduced in cell 
lines and found to be of functional significance.229,230  
Another issue to take into consideration is target vulnerability, e.g., receptor desensitization, 
internalization, degradation and recycling.88 The A2A231, A2B232 and A3233 ARs have all been 
observed with rapid desensitization upon agonist treatment, with A3AR desensitization the faster 
process.234 Posttranslational target modifications such as phosphorylation and ubiquitination also 
affect the target’s half-life of A2A235, A2B236 and A3237 ARs leading to the recruitment of arrestins 
and subsequent sequestration from the plasma membrane. In contrast, A1AR desensitization 
requires prolonged exposure to agonists and it is still controversial whether phosphorylation 
actually occurs.234 As such, ligand-receptor binding kinetics will be significantly influenced with 
two possible yet opposite consequences: (1) internalization of a receptor via endocytic vesicles to 
the lysosome or vacuole for degradation leading to termination of the ligand-receptor residence 
time;238 (2) internalized ligand-receptor complex “traps” the ligand within an intracellular 
compartment preventing it from diffusion and thereby inducing rebinding.239 Both mechanisms 
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seem to be possible and have not yet been explored for the ARs. Thus, further experiments for 
different ligand-receptor pairs are needed. Additionally, it will be of great value to obtain 
information regarding the synthesis and degradation process of ARs, the rates of which may 
affect the impact of a ligand’s binding kinetics. 
 
6. CONCLUDING REMARKS 
In this review we have shown that kinetics is an emerging parameter to probe ligand-receptor 
interactions which can provide additional information to direct medicinal chemistry efforts. It 
may support the triage and further advancement of compounds in the drug discovery pipeline that 
are otherwise chemically or biologically similar. This has been illustrated already in several 
SAR/SKR studies on the A1 and A2A ARs, in which equipotent compounds but with divergent 
kinetics were obtained.72,73,106  
Investigations of binding kinetics also aid the identification and characterization of novel or 
known (AR) allosteric modulators. By comparing the kinetics of an orthosteric ligand in the 
absence or presence of an allosteric modulator, one can study the typical modulating effects such 
as “probe-dependence” or “concentration-dependency” of an allosteric modulator. It is also 
notable that an allosteric modulator can induce significant effects on not only the off-rate but also 
the on-rate of an orthosteric ligand, although the latter has been less investigated. Association rate 
constants may be important as well to delineate the molecular basis of GPCR allosterism.57,74,240 
Taken together, examples presented in this review make a strong case for the value of 
measuring ligand-receptor binding kinetics in early phases of drug design and discovery. We 
anticipate that a fast accumulation of AR binding kinetics will take place in the near future, which 
hopefully will lead to the identification of novel and better-in-class candidate drugs, targeting 
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 Figure 1. A2AAR crystal structures in complex with ZM241385 (A, PDB: 4EIY) and UK432,097 




 Figure 2. Current methods to measure binding kinetics on adenosine receptors. (A) Kinetic 
ligand association assay. The assay is initiated by incubating a labeled ligand (e.g.,  radioligand, 
orange spheres) with the receptor. After a period of incubation, the association approaches 
equilibrium caused by the formation of the ligand-receptor binary complex (B) Kinetic ligand 
dissociation assay. The receptor-bearing material is firstly equilibrated with the labeled ligand 
(e.g., radioligand, orange spheres) and then a saturating concentration of unlabeled competitor 
(blue spheres) is added to prevent the labeled ligand from reassociating to the receptor. After a 
period of incubation, the dissociation of the labeled ligand is complete with receptor binding sites 
fully occupied by the competitor. (C) Competition association assay. The association of a labeled 
ligand (e.g., radioligand, orange spheres) is initiated in the absence (i) or presence of an unlabeled 
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ligand (blue spheres, ii and iii). In the presence of a fast dissociating compound, the specific 
binding of the labeled ligand slowly and monotonically approaches equilibrium in time (ii).  In 
the presence of a slowly dissociating compound, the specific binding of the labeled ligand 
consists of two phases starting with an ‘overshoot’ and then a decline until a new equilibrium is 
reached (iii). (D) Kinetic assay in the presence of an allosteric modulator. Formation of the 
ligand-receptor binary complex is initiated by preincubating the receptor-bearing material with 
the labeled ligand (e.g., radioligand, orange spheres). An allosteric modulator (red triangles) is 
then added, stabilizing the allosteric ternary complex, together with an excess amount of an 
unlabeled competitor (blue spheres) to start the dissociation of the labeled ligand. After a period 
of incubation, the allosteric activity is evaluated based on a comparison between the residually 
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Figure 12. The structure of the human M2 muscarinic acetylcholine receptor in complex with an 
orthosteric ligand, iperoxo, and an allosteric modulator, LY2119620 (PDB: 4MQT).  
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